Compare Royal Caribbean Cruises Ltd (RCL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Royal Caribbean Cruises Ltd trades at $284.94 (market cap $75.51B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RCL | VRTX | |
|---|---|---|
Market Cap | $75.51B | $128.16B |
Volume | 2,408,997 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $557.96 |
52-Week Low | $230.30 | $407.37 |
Typical Hold Time | 85 Days | 120 Days |
Enterprise Value | $98.15B | $122.29B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $282.36, down 2.25% today but maintains strong fundamentals with robust revenue growth from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.27B. The technical picture is bullish with support at $280 and resistance at $287, while analyst consensus favors Buy ratings (51%) with a $346.67 price target. Recent news highlights the $3B Sandals Resorts stake expansion and positive industry momentum from Carnival's strong results.
RCL presents a compelling growth story with expanding margins and strategic diversification, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current valuation at 17.44x P/E offers room for upside relative to analyst targets, supported by consistent earnings beats and bullish institutional sentiment.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
